1 Robert H. Lurie Comprehensive Cancer Center of Northwestern University; UCSF Helen Diller Family Comprehensive Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Vanderbilt-Ingram Cancer Center; City of Hope Comprehensive Cancer Center; Fox Chase Cancer Center; Dana-Farber/Brigham and Women's Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Fred & Pamela Buffett Cancer Center; Mayo Clinic Cancer Center; Yale Cancer Center/Smilow Cancer Hospital; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; University of Alabama at Birmingham Comprehensive Cancer Center; Stanford Cancer Institute; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance; University of Colorado Cancer Center; UC San Diego Moores Cancer Center; Roswell Park Cancer Institute; The University of Texas MD Anderson Cancer Center; Massachusetts General Hospital Cancer Center; Memorial Sloan Kettering Cancer Center; Huntsman Cancer Institute at the University of Utah; Moffitt Cancer Center; University of Michigan Comprehensive Cancer Center; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Duke Cancer Institute; and National Comprehensive Cancer Network.
The NCCN Guidelines for Rectal Cancer begin with the clinical presentation of the patient to the primary care physician or gastroenterologist and address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease, and survivorship. The NCCN Rectal Cancer Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize major discussion points from the 2015 NCCN Rectal Cancer Panel meeting. Major discussion topics this year were perioperative therapy options and surveillance for patients with stage I through III disease.
Provided content development and/or authorship assistance.